Silo Pharma, Inc. (SILO)
1.458
-0.04
(-2.80%)
USD |
NASDAQ |
Oct 02, 16:00
1.21
-0.25
(-17.01%)
After-Hours: 20:00
Silo Pharma Enterprise Value : -3.787M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | -3.787M |
| October 01, 2026 | -3.740M |
| September 30, 2026 | -3.728M |
| September 29, 2026 | -3.616M |
| September 28, 2026 | -3.570M |
| September 25, 2026 | -3.458M |
| September 24, 2026 | -3.458M |
| September 23, 2026 | -3.435M |
| September 22, 2026 | -3.492M |
| September 21, 2026 | -3.463M |
| September 18, 2026 | -3.356M |
| September 17, 2026 | -3.492M |
| September 16, 2026 | -3.446M |
| September 15, 2026 | -3.243M |
| September 14, 2026 | -3.096M |
| September 11, 2026 | -3.063M |
| September 10, 2026 | -3.058M |
| September 09, 2026 | -3.006M |
| September 08, 2026 | -2.860M |
| September 04, 2026 | -2.724M |
| September 03, 2026 | -2.668M |
| September 02, 2026 | -2.611M |
| September 01, 2026 | -2.679M |
| August 31, 2026 | -2.634M |
| August 28, 2026 | -2.566M |
| Date | Value |
|---|---|
| August 27, 2026 | -2.566M |
| August 26, 2026 | -2.611M |
| August 25, 2026 | -2.510M |
| August 24, 2026 | -2.521M |
| August 21, 2026 | -2.442M |
| August 20, 2026 | -2.340M |
| August 19, 2026 | -2.205M |
| August 18, 2026 | -1.968M |
| August 17, 2026 | -1.968M |
| August 14, 2026 | -1.821M |
| August 13, 2026 | -1.799M |
| August 12, 2026 | -1.940M |
| August 11, 2026 | -1.415M |
| August 10, 2026 | -1.167M |
| August 07, 2026 | -1.217M |
| August 06, 2026 | -0.1621M |
| August 05, 2026 | -0.2299M |
| August 04, 2026 | -0.2411M |
| August 03, 2026 | -0.5571M |
| July 31, 2026 | -0.7039M |
| July 30, 2026 | -0.6361M |
| July 29, 2026 | -0.5797M |
| July 28, 2026 | -0.3991M |
| July 27, 2026 | -0.4669M |
| July 24, 2026 | -0.3879M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
| Vericel Corp. | 1.987B |
| Biogen, Inc. | 39.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.8328M |
| Total Expenses (Quarterly) | 0.8328M |
| EPS Diluted (Quarterly) | -0.7581 |
| Earnings Yield | -366.1% |
| Normalized Earnings Yield | -358.48 |